Molecular, Pathophysiological, and Clinical Aspects of Corticosteroid-Induced Neuropsychiatric Effects: From Bench to Bedside
Sara Sofía-Avendaño-Lopez,
Angela Johanna Rodríguez-Marín,
Mateo Lara-Castillo,
Juanita Agresott-Carrillo,
Luna Estefanía Lara-Cortés,
Juan Felipe Sánchez-Almanzar,
Sophya Villamil-Cruz,
Luis Carlos Rojas-Rodríguez,
Daniel Felipe Ariza-Salamanca,
Mariana Gaviria-Carrillo,
Carlos Alberto Calderon-Ospina,
Jesús Rodríguez-Quintana
Affiliations
Sara Sofía-Avendaño-Lopez
Social Epidemiology Research Team, Institut Pierre Louis d’Epidémiologie et de Santé Publique, INSERM, Sorbonne Université, F 75012 Paris, France
Angela Johanna Rodríguez-Marín
Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Mateo Lara-Castillo
Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Juanita Agresott-Carrillo
Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Luna Estefanía Lara-Cortés
Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Juan Felipe Sánchez-Almanzar
Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Sophya Villamil-Cruz
Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Luis Carlos Rojas-Rodríguez
Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Daniel Felipe Ariza-Salamanca
Department of Pharmacobiology, Center for Research and Advanced Studies (Cinvestav), National Polytechnic Institute, Mexico City 14300, Mexico
Mariana Gaviria-Carrillo
Neuroscience Research Group (NeURos), NeuroVitae Center for Neuroscience, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Carlos Alberto Calderon-Ospina
Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia
Jesús Rodríguez-Quintana
Fundacion CardioInfantil-Instituto de Cardiología, Bogotá 111156, Colombia
Corticosteroids are frequently prescribed across medical disciplines, yet they are associated with various adverse effects, including neuropsychiatric symptoms, documented since their introduction over 60 years ago. The cellular mechanisms underlying neuropsychiatric symptoms are complex and somewhat obscure, involving multiple pathways. Notably, they include changes in excitability, cellular death of hippocampal and striatal neurons, and increased inflammation and oxidative stress. Clinical presentation varies, encompassing affective disorders (anxiety, euphoria, depression), psychotic episodes, and cognitive deficits. It is crucial to note that these manifestations often go unnoticed by treating physicians, leading to delayed detection of severe symptoms, complications, and underreporting. Discontinuation of corticosteroids constitutes the cornerstone of treatment, resolving symptoms in up to 80% of cases. Although the literature on this topic is scant, isolated cases and limited studies have explored the efficacy of psychotropic medications for symptomatic control and prophylaxis. Pharmacological intervention may be warranted in situations where corticosteroid reduction or withdrawal is not feasible or beneficial for the patient.